Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents summary results of the Company’s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):

	Three Months Ended March 31,
	2025		2024
Cell Engineering
Revenue	$	38,230	$	27,889
Costs and operating expenses:
Cost of other revenue	3,121		—
Research and development	48,670		81,898
General and administrative	18,027		38,244
Cell Engineering operating loss	(31,588)		(92,253)
Biosecurity
Revenue	10,088		10,055
Costs and operating expenses:
Cost of Biosecurity revenue	7,223		9,202
Research and development	—		120
General and administrative	8,050		11,951
Biosecurity operating loss	(5,185)		(11,218)
Total segment operating loss	(36,773)		(103,471)
Reconciling items to reconcile total segment operating loss to loss before income taxes:
Stock-based compensation (1)	20,800		42,397
Depreciation and amortization	15,366		12,869
Restructuring charges (2)	5,273		—
Carrying cost of excess space (net of sublease income) (3)	11,674		—
Merger and acquisition related expense (income) (4)	(918)		2,394
Acquired in-process research and development	—		16,871
Other (income) expense, net (5)	1,901		(12,122)
Loss before income taxes	$	(90,869)	$	(165,880)

(1) Includes $0.4 million and $1.6 million in employer payroll taxes for the three months ended March 31, 2025 and 2024, respectively.

(2)See Note 3, Restructuring, for composition of costs.

(3)The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.

(4)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs.

(5)Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.